Teva warns on profit as drugmaker's problems deepen

By Steven Scheer and Ari RabinovitchJERUSALEM (Reuters) - Teva Pharmaceutical Industries, the world's biggest generic medicine maker, said it would miss 2017 profit forecasts due to competition in the U.S. market and weakening sales of its multiple sclerosis drug Copaxone, hammering its sharesIt was the latest blow for the Israeli-based company, which is dealing with narrowing profit margins, a nearly $35 billion debt burden that could lead to a credit rating downgrade, and an irate investor bas